A Phase 2, Double-Blind, Randomized, Placebo-Controlled Study of FG-3019 in Subjects With Liver Fibrosis Due to Chronic Hepatitis B Infection
Phase of Trial: Phase II
Latest Information Update: 17 Aug 2016
Price : $35 *
At a glance
- Drugs Pamrevlumab (Primary)
- Indications Hepatic fibrosis; Hepatitis B
- Focus Therapeutic Use
- Sponsors FibroGen
- 12 Aug 2016 Status changed from active, no longer recruiting to discontinued.
- 06 Jan 2015 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov record.
- 04 Sep 2014 New trial record